TOP > 外国特許検索 > SPECIFIC MODIFICATION OF ANTIBODY BY IgG-BINDING PEPTIDE

SPECIFIC MODIFICATION OF ANTIBODY BY IgG-BINDING PEPTIDE コモンズ 新技術説明会

外国特許コード F160008762
整理番号 14P058WO
掲載日 2016年6月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP065061
国際公開番号 WO 2016186206
国際出願日 平成28年5月20日(2016.5.20)
国際公開日 平成28年11月24日(2016.11.24)
優先権データ
  • 特願2015-103153 (2015.5.20) JP
発明の名称 (英語) SPECIFIC MODIFICATION OF ANTIBODY BY IgG-BINDING PEPTIDE コモンズ 新技術説明会
発明の概要(英語) The present invention pertains to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a complex of IgG and said IgG-binding peptide modified with a cross-linking agent, and a method for preparing said complex.
特許請求の範囲(英語) [claim1]
1. The below-mentioned formula I:
(X [1-3]) - C- (X [2]) - H- (Xaa1) - G- (Xaa2) - L-V-W-C- (X [1-3]) (i)
(In formula, X each is the optional amino acid residue other than cystein independently,
C is the cystein residue,
H is the histidine residue,
Xaa1 the ricin residue, the cystein residue, the aspartic acid residue and the glutamic acid residue, 2 - is amino suberin acid or diamino propionic acid,
G is the glycine residue,
Xaa2 is the glutamic acid residue or the asparagine residue,
L is the leucine residue,
V to be the valine residue, at the same time
W is the [toriputohuan] residue.)
The amino acid arrangement which is displayed by, consists of the 13-17 amino acid residue is included, at the same time person IgG and/or rabbit IgG and connection the peptide which features that it is possible.
[claim2]
2. The below-mentioned formula II:
(X [1-3]) - C- (Xaa3) - (Xaa4) - H- (Xaa1) - G- (Xaa2) - L-V-W-C- (X [1-3]) (ii)
(In formula, X each is the optional amino acid residue other than cystein independently,
C is the cystein residue,
H is the histidine residue,
Xaa1 the ricin residue, the cystein residue, the aspartic acid residue and the glutamic acid residue, 2 - is amino suberin acid or diamino propionic acid,
G is the glycine residue,
Xaa2 is the glutamic acid residue or the asparagine residue,
L is the leucine residue,
V is the valine residue,
W is the [toriputohuan] residue,
Xaa3 to be the alanine residue, the ceric residue or the [toreonin] residue, at the same time
Xaa4 is the thyrosin residue or the [toriputohuan] residue.)
It includes the amino acid arrangement which is displayed by, consists of the 13-17 amino acid residue at the same time person IgG and/or rabbit IgG and it features that it is connection possible, in claim 1 the peptide of statement.
[claim3]
3. The below-mentioned formula III:
(X [1-3]) - C-A-Y-H- (Xaa1) - G-E-L-V-W-C- (X [1-3]) (iii)
(In formula, X each is the optional amino acid residue other than cystein independently,
C is the cystein residue,
A is the alanine residue,
Y is the thyrosin residue,
H is the histidine residue,
Xaa1 the ricin residue, the cystein residue, the aspartic acid residue and the glutamic acid residue, 2 - is amino suberin acid or diamino propionic acid,
G is the glycine residue,
E is the glutamic acid residue,
L is the leucine residue,
V to be the valine residue, at the same time
W is the [toriputohuan] residue.)
It includes the amino acid arrangement which is displayed by, consists of the 13-17 amino acid residue at the same time person IgG and/or rabbit IgG and it features that it is connection possible, in claim 1 or 2 the peptide of statement.
[claim4]
4. It makes 17 amino acid residues, from N end when each amino acid residue of the 1-3 and the 15-17 turn eye,
1st amino acid residue = S, G and F or, it is not
2nd amino acid residue = D, G, A, S and P, homo- cystein, or, it is not
3rd amino acid residue = S, D, T, N, E or R,
15th amino acid residue = S, T or D,
16th amino acid residue = H, G, Y, T, N, D and F, homo- cystein, or, it is not,
17th amino acid residue = Y, F and H, M or, it is not
So it is, either of the claim 1-3 in one section the peptide of statement.
[claim5]
5. 1) the -15 below) it consists of each amino acid arrangement, however, Xaa1 the ricin residue, the cystein residue, the aspartic acid residue and the glutamic acid residue, 2 - is amino suberin acid or diamino propionic acid, Xaa2 is homo- cystein, in claim 4 the peptide of statement.
1) DCAYH (Xaa1) GELVWCT (SEQ ID NO 1)
2) GPDCAYH (Xaa1) GELVWCTFH (SEQ ID NO 2)
3) RCAYH (Xaa1) GELVWCS (SEQ ID NO 3)
4) GPRCAYH (Xaa1) GELVWCSFH (SEQ ID NO 4)
5) SPDCAYH (Xaa1) GELVWCTFH (SEQ ID NO 5)
6) GDDCAYH (Xaa1) GELVWCTFH (SEQ ID NO 6)
7) GPSCAYH (Xaa1) GELVWCTFH (SEQ ID NO 7)
8) GPDCAYH (Xaa1) GELVWCSFH (SEQ ID NO 8)
9) GPDCAYH (Xaa1) GELVWCTHH (SEQ ID NO 9)
10) GPDCAYH (Xaa1) GELVWCTFY (SEQ ID NO 10)
11) SPDCAYH (Xaa1) GELVWCTFY (SEQ ID NO 11)
12) SDDCAYH (Xaa1) GELVWCTFY (SEQ ID NO 12)
13) RGNCAYH (Xaa1) GQLVWCTYH (SEQ ID NO 13)
14) G (Xaa2) DCAYH (Xaa1) GELVWCT (Xaa2) H (SEQ ID NO 36)
15) RRGPDCAYH (Xaa1) GELVWCTFH (SEQ ID NO 37)
[claim6]
6. The below-mentioned formula IV:
D-C- (Xaa3) - (Xaa4) - H- (Xaa1) - G- (Xaa2) - L-V-W-C-T (iv)
(In formula,
D is the aspartic acid residue,
C is the cystein residue,
H is the histidine residue,
Xaa1 the ricin residue, the cystein residue, the aspartic acid residue and the glutamic acid residue, 2 - is amino suberin acid or diamino propionic acid,
G is the glycine residue,
Xaa2 is the glutamic acid residue or the asparagine residue,
L is the leucine residue,
V is the valine residue,
W is the [toriputohuan] residue,
T is the [toreonin] residue,
Xaa3 to be the alanine residue or the [toreonin] residue, at the same time,
Xaa4 is the thyrosin residue or the [toriputohuan] residue.)It includes the amino acid arrangement which is displayed by, consists of 13 amino acid residues at the same time person IgG and/or rabbit IgG and it features that it is connection possible, in claim 1 or 2 the peptide of statement.
[claim7]
7. 1) the -4 below) it consists of each amino acid arrangement, however, Xaa1 the ricin residue, the cystein residue, the aspartic acid residue and the glutamic acid residue, 2 - is amino suberin acid or diamino propionic acid, in claim 6 the peptide of statement.
1) DCTYH (Xaa1) GNLVWCT (SEQ ID NO 14)
2) DCAYH (Xaa1) GNLVWCT (SEQ ID NO 15)
3) DCTYH (Xaa1) GELVWCT (SEQ ID NO 16)
4) DCAWH (Xaa1) GELVWCT (SEQ ID NO 17)
[claim8]
8. The below-mentioned formula V:
D-C- (Xaa2) - (Xaa3) - (Xaa4) - (Xaa1) - G- (Xaa5) - L- (Xaa6) - W-C-T (v)
(In formula,
D is the aspartic acid residue,
C is the cystein residue,
G is the glycine residue,
L is the leucine residue,
W is the [toriputohuan] residue,
T is the [toreonin] residue,
Xaa1 the ricin residue, the cystein residue, the aspartic acid residue and the glutamic acid residue, 2 - is amino suberin acid or diamino propionic acid,
Xaa2 is the alanine residue, the ceric residue or the [toreonin] residue,
Xaa3 is the [toriputohuan] residue or the thyrosin residue,
Xaa4 is the histidine residue, the arginine residue, the ceric residue or the [toreonin] residue,
Xaa5 to be the glutamic acid residue, the asparagine residue, the arginine residue or the aspartic acid residue, at the same time
The amino acid arrangement where Xaa6 is displayed it is the isoleucine residue or the valine residue) by, consists of 13 amino acid residues is included, at the same time person IgG and/or rabbit IgG and connection the peptide which features that it is possible.
[claim9]
9. Peptide two cystein outside (C) forms disulfide bond between the residues or, or the sulfide basis in two cystein residues outside peptide, formula below:
It is connected so by the linker which is displayed, either of the claim 1-8 in one section the peptide of statement.
[claim10]
10. The sign it is done by the sign substance, either of the claim 1-9 in one section the peptide of statement.
[claim11]
11. The medicine has connected, either of the claim 1-10 in one section the peptide of statement.
[claim12]
12. Xaa1 is the ricin residue, either of the claim 1-11 in one section the peptide of statement.
[claim13]
13. Xaa1 is decorated with the building a bridge medicine, either of the claim 1-12 in one section the peptide of statement.
[claim14]
14. The aforementioned building a bridge medicine, DSG ([jisukushinimijirugurutareto]), DSS ([jisukushinimijirusubereto]), DMA ([ajipuimido] acid dimethyl two hydrochloride), DMP ([pimeruimido] acid dimethyl two hydrochloride), DMS ([suberuimido] acid dimethyl two hydrochloride), DTBP (3,3 ' - [jichiobisupuropionimido] acid dimethyl two hydrochloride), and DSP ([jichiobisusukushinimijirupuropion] acid) is selected from the group which consists of, in claim 13 the peptide of statement.
[claim15]
15. The aforementioned building a bridge medicine is DSG ([jisukushinimijirugurutareto]) or DSS ([jisukushinimijirusubereto]), in claim 14 the peptide of statement.
[claim16]
16. Either of the claim 13-15 being the mixture of peptide and IgG of statement in one section, it is formed by the building a bridge reaction of peptide and IgG which are decorated with the building a bridge medicine, the aforementioned mixture.
[claim17]
17. Either of the claim 13-15 peptide and IgG of statement are mixed into one section, peptide and IgG which are decorated with the building a bridge medicine the process which it builds a bridge reacts is included, the method the mixture of peptide and IgG being produced.
[claim18]
18. Either of the claim 1-15 the mixture of statement is included in the peptide, or claim 16 of statement in one section, the medicine composition.
[claim19]
19. Formula of peptide and below two or more it includes the cystein residue:
So is displayed the chemical compound which (in formula, R [1] and R [2], each it is the optional halogen atom independently) to mix, the sulfide basis in the cystein residue of two or more, formula below:
The process which obtains the peptide which is connected so by the linker which is displayed is included, the cystein residue of two or more the method of producing the peptide which is connected by linker.
[claim20]
20. In the aforementioned chemical compound, R [1] and R [2] is identical, at the same time Cl and Br, or is I, in claim 19 method of statement.
[claim21]
21. The aforementioned peptide, the claim 1-8 and either of the 10-15 is the peptide which is stipulated in one section, in claim 19 or 20 method of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • ITO YUJI
国際特許分類(IPC)
指定国 (WO2016186206)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) AMED Basic Science and Plateform Tachnolohgy Program for Innovative Biological Medicine AREA
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close